Clinical trialNCT05251909TerminatedPhase 3Interventional

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

SponsorAstraZenecaEnrollment12Eosinophilic GastritisEosinophilic Gastroenteritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 3-part study. Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease. After completing Part A, participants can continue to Part C - open-label benralizumab treatment period. Following the decision to close enrollment, patients in both Part A and Part C will be given the option to proceed to 6-months of open-label benralizumab treatment in Part D.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marc E. Rothenberg, MD, PhD
Cincinnati Children's Hospital Medical Center 3333 Burnet Ave, Cincinnati Ohio 45229, United States
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Research Site
São Paulo, Brazil

Italy

Research Site
Milan, Italy
Research Site
Padova, Italy
Research Site
Pisa, Italy

Japan

Research Site
Bunkyō City, Japan
Research Site
Maebashi, Japan
Research Site
Ogaki-shi, Japan
Research Site
Shinjuku-ku, Japan

Netherlands

Research Site
Amsterdam, Netherlands

Poland

Research Site
Staszów, Poland

Spain

Research Site
Seville, Spain

Ukraine

Research Site
Kyiv, Ukraine

United States

Research Site
Chicago, Illinois, United States
Research Site
Boston, Massachusetts, United States
Research Site
Rochester, Minnesota, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Salt Lake City, Utah, United States

Vietnam

Research Site
Hanoi, Vietnam

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Benralizumab →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Jan 2022
Primary completion: 13 Feb 2024
Completion: 13 Feb 2024
Last update posted: 14 Jul 2025
Registered enrollment: 12
Registry id: NCT05251909

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-000085-14

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.